{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:11:11Z","timestamp":1791882671508,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-09763-6","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T08:02:18Z","timestamp":1725264138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The safety of a dolutegravir (DTG)-based antiretroviral treatment (ART) regimen for pregnancy and birth outcomes in Ethiopia: evidence from multicenter cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Abel","family":"Gedefaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birkneh Tilahun","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifru","family":"Berhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyasu","family":"Makonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Vella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"issue":"3","key":"9763_CR1","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/S1473-3099(17)30482-6","volume":"18","author":"N Ford","year":"2018","unstructured":"Ford N, Ball A, Baggaley R, Vitoria M, Low-Beer D, Penazzato M, et al. The WHO public health approach to HIV treatment and care: looking back and looking ahead. Lancet Infect Dis. 2018;18(3):e76\u201386.","journal-title":"Lancet Infect Dis"},{"key":"9763_CR2","unstructured":"estimates UW. HIV statistics, globally and by WHO Region, 2023.: World Health Organization e2023 [cited 2023 October 26 ]. https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-hiv-hepatitis-and-stis-library\/j0294-who-hiv-epi-factsheet-v7.pdf?sfvrsn=5cbb3393_7"},{"key":"9763_CR3","unstructured":"Organization WH. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach-2010 version. World Health Organization; 2010."},{"key":"9763_CR4","doi-asserted-by":"crossref","unstructured":"Husaeni N, Cusmarih C, editors. Meta-Analysis: The Effect of HIV\/AIDS in Pregnant Women Against the Incidence of Low Birth Weight and Preterm Birth. Proceedings of the International Conference on Nursing and Health Sciences; 2023.","DOI":"10.37287\/picnhs.v4i1.1800"},{"key":"9763_CR5","unstructured":"Organization WH. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations: World Health Organization; 2016 [cited 2024 May 01]. https:\/\/www.who.int\/publications-detail-redirect\/9789241511124"},{"key":"9763_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40121-014-0029-7","volume":"3","author":"DE Dow","year":"2014","unstructured":"Dow DE, Bartlett JA. Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV. Infect Dis Therapy. 2014;3:83\u2013102.","journal-title":"Infect Dis Therapy"},{"key":"9763_CR7","doi-asserted-by":"crossref","unstructured":"Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400\u00a0mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. EClinicalMedicine. 2020;28.","DOI":"10.1016\/j.eclinm.2020.100573"},{"key":"9763_CR8","unstructured":"Llibre JM, Pulido F, Garc\u00eda F, Garcia Deltoro M, Blanco JL, Delgado R. Genetic barrier to resistance for dolutegravir. AIDS Rev. 2015;17(1)."},{"key":"9763_CR9","unstructured":"Organization WH. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach: World Health Organization; 2021 [cited 2024 May 01]. https:\/\/www.who.int\/publications-detail-redirect\/9789240031593"},{"issue":"7","key":"9763_CR10","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/cid\/ciz121","volume":"69","author":"A Colbers","year":"2019","unstructured":"Colbers A, Mirochnick M, Schalkwijk S, Penazzato M, Townsend C, Burger D. Importance of prospective studies in pregnant and Breastfeeding women Living with Human Immunodeficiency Virus. Clin Infect Dis. 2019;69(7):1254\u20138.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"9763_CR11","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1016\/j.whi.2012.10.003","volume":"23","author":"MC Blehar","year":"2013","unstructured":"Blehar MC, Spong C, Grady C, Goldkind SF, Sahin L, Clayton JA. Enrolling pregnant women: issues in clinical research. Women\u2019s Health Issues. 2013;23(1):e39\u201345.","journal-title":"Women\u2019s Health Issues"},{"issue":"10281","key":"9763_CR12","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(21)00314-7","volume":"397","author":"S Lockman","year":"2021","unstructured":"Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, et al. Efficacy and safety of dolutegravir-and tenofovir alafenamide fumarate-containing HIV antiretroviral treatment regimens started in pregnancy: a randomised controlled trial. Lancet (London England). 2021;397(10281):1276.","journal-title":"Lancet (London England)"},{"issue":"5","key":"9763_CR13","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(20)30050-3","volume":"7","author":"K Kintu","year":"2020","unstructured":"Kintu K, Malaba TR, Nakibuka J, Papamichael C, Colbers A, Byrne K, et al. Dolutegravir versus Efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial. Lancet HIV. 2020;7(5):e332\u20139.","journal-title":"Lancet HIV"},{"issue":"8","key":"9763_CR14","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S2352-3018(22)00173-4","volume":"9","author":"TR Malaba","year":"2022","unstructured":"Malaba TR, Nakatudde I, Kintu K, Colbers A, Chen T, Reynolds H, et al. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. Lancet HIV. 2022;9(8):e534\u201343.","journal-title":"Lancet HIV"},{"issue":"9","key":"9763_CR15","doi-asserted-by":"publisher","first-page":"e1002895","DOI":"10.1371\/journal.pmed.1002895","volume":"16","author":"C Waitt","year":"2019","unstructured":"Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study). PLoS Med. 2019;16(9):e1002895.","journal-title":"PLoS Med"},{"issue":"1","key":"9763_CR16","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2352-3018(16)30195-3","volume":"4","author":"OA Uthman","year":"2017","unstructured":"Uthman OA, Nachega JB, Anderson J, Kanters S, Mills EJ, Renaud F, et al. Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. Lancet HIV. 2017;4(1):e21\u201330.","journal-title":"Lancet HIV"},{"key":"9763_CR17","unstructured":"Organization WH. The importance of pharmacovigilance 2002 [cited 2024 May 1]. https:\/\/www.paho.org\/en\/documents\/importance-pharmacovigilance-2002-who"},{"key":"9763_CR18","unstructured":"Organization WH. A practical handbook on the pharmacovigilance of antiretroviral medicines. World Health Organization; 2009."},{"issue":"7","key":"9763_CR19","doi-asserted-by":"publisher","first-page":"e804","DOI":"10.1016\/S2214-109X(18)30218-3","volume":"6","author":"R Zash","year":"2018","unstructured":"Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Lancet Global Health. 2018;6(7):e804\u201310.","journal-title":"Lancet Global Health"},{"issue":"1","key":"9763_CR20","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2352-3018(20)30268-X","volume":"8","author":"GFM Pereira","year":"2021","unstructured":"Pereira GFM, Kim A, Jalil EM, Fonseca FF, Shepherd BE, Veloso VG, et al. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. Lancet HIV. 2021;8(1):e33\u201341.","journal-title":"Lancet HIV"},{"key":"9763_CR21","doi-asserted-by":"publisher","first-page":"e25922","DOI":"10.1002\/jia2.25922","volume":"25","author":"F Renaud","year":"2022","unstructured":"Renaud F, Mofenson LM, Bakker C, Dolk H, Leroy V, Namiba A, et al. Surveillance of ARV safety in pregnancy and breastfeeding: towards a new framework. J Int AIDS Soc. 2022;25:e25922.","journal-title":"J Int AIDS Soc"},{"key":"9763_CR22","unstructured":"Group WB. Ethiopia overview World bank in Ethiopia; 2024 [cited 2024 June 23, 2024]. https:\/\/www.worldbank.org\/en\/country\/ethiopia\/overview"},{"key":"9763_CR23","unstructured":"Prevention FHA, Office C. HIV Prevention in Ethiopia National Road Map 2018\u20132020. Federal HIV\/AIDS Prevention and Control Office Addis Ababa; 2018."},{"key":"9763_CR24","unstructured":"Ethiopia MoHo. Revised Technical and procedural guidelines for safe abortion services in Ethiopia: WHO. 2014 [cited 2024 June 23]. https:\/\/platform.who.int\/docs\/default-source\/mca-documents\/policy-documents\/guideline\/ETH-RH-18-01-GUIDELINE-2014-eng-Safe-Abortion-Services.pdf"},{"key":"9763_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12884-017-1266-z","volume":"17","author":"Y Dibaba","year":"2017","unstructured":"Dibaba Y, Dijkerman S, Fetters T, Moore A, Gebreselassie H, Gebrehiwot Y, et al. A decade of progress providing safe abortion services in Ethiopia: results of national assessments in 2008 and 2014. BMC Pregnancy Childbirth. 2017;17:1\u201312.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"10409","key":"9763_CR26","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0140-6736(23)00878-4","volume":"402","author":"EO Ohuma","year":"2023","unstructured":"Ohuma EO, Moller A-B, Bradley E, Chakwera S, Hussain-Alkhateeb L, Lewin A, et al. National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis. Lancet. 2023;402(10409):1261\u201371.","journal-title":"Lancet"},{"key":"9763_CR27","unstructured":"Br\u00e4mer GR. International statistical classification of diseases and related health problems. Tenth revision. World health statistics quarterly Rapport trimestriel de statistiques sanitaires mondiales. 1988;41(1):32\u2009\u2013\u20096."},{"key":"9763_CR28","unstructured":"Organization WH. Global nutrition targets 2025: stunting policy brief. World Health Organization; 2014."},{"issue":"3","key":"9763_CR29","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1097\/AOG.0000000000002820","volume":"132","author":"Obstetricians","year":"2018","unstructured":"Obstetricians, ACo. Gynecologists. ACOG committee opinion 751: labor and delivery management of women living with human immunodeficiency virus. Obstet Gynecol. 2018;132(3):e131\u20137.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"9763_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/QAI.0000000000002035","volume":"81","author":"V Vannappagari","year":"2019","unstructured":"Vannappagari V, Thorne C. Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir. J Acquir Immune Defic Syndr. 2019;81(4):371.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"9763_CR31","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1473-3099(06)70629-6","volume":"6","author":"AP Kourtis","year":"2006","unstructured":"Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis. 2006;6(11):726\u201332.","journal-title":"Lancet Infect Dis"},{"key":"9763_CR32","doi-asserted-by":"crossref","unstructured":"Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to\u2010child transmission of HIV infection. Cochrane Database Syst Reviews. 2011(7).","DOI":"10.1002\/14651858.CD003510.pub3"},{"issue":"1","key":"9763_CR33","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1186\/s12884-020-03271-6","volume":"20","author":"KF Muchie","year":"2020","unstructured":"Muchie KF, Lakew AM, Teshome DF, Yenit MK, Sisay MM, Mekonnen FA, et al. Epidemiology of preterm birth in Ethiopia: systematic review and meta-analysis. BMC Pregnancy Childbirth. 2020;20(1):574.","journal-title":"BMC Pregnancy Childbirth"},{"key":"9763_CR34","doi-asserted-by":"publisher","first-page":"2426891","DOI":"10.1155\/2021\/2426891","volume":"2021","author":"S Gedamu","year":"2021","unstructured":"Gedamu S, Sendo EG, Daba W. Congenital Anomalies and Associated Factors among newborns in Bishoftu General Hospital, Oromia, Ethiopia: a retrospective study. J Environ Public Health. 2021;2021:2426891.","journal-title":"J Environ Public Health"},{"key":"9763_CR35","doi-asserted-by":"crossref","unstructured":"Gedefaw A, Teklu S, Tadesse BT. Magnitude of neural tube defects and associated risk factors at three teaching hospitals in Addis Ababa, Ethiopia. BioMed Research International. 2018;2018.","DOI":"10.1155\/2018\/4829023"},{"issue":"11","key":"9763_CR36","doi-asserted-by":"publisher","first-page":"e077685","DOI":"10.1136\/bmjopen-2023-077685","volume":"13","author":"N Tesfay","year":"2023","unstructured":"Tesfay N, Hailu G, Habtetsion M, Woldeyohannes F. Birth prevalence and risk factors of neural tube defects in Ethiopia: a systematic review and meta-analysis. BMJ open. 2023;13(11):e077685.","journal-title":"BMJ open"},{"issue":"1","key":"9763_CR37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12883-022-02697-z","volume":"22","author":"P Ssentongo","year":"2022","unstructured":"Ssentongo P, Heilbrunn ES, Ssentongo AE, Ssenyonga LV, Lekoubou A. Birth prevalence of neural tube defects in eastern Africa: a systematic review and meta-analysis. BMC Neurol. 2022;22(1):202.","journal-title":"BMC Neurol"},{"key":"9763_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12887-021-02653-9","volume":"21","author":"M Oumer","year":"2021","unstructured":"Oumer M, Tazebew A, Silamsaw M. Birth prevalence of neural tube defects and associated risk factors in Africa: a systematic review and meta-analysis. BMC Pediatr. 2021;21:1\u201313.","journal-title":"BMC Pediatr"},{"issue":"5","key":"9763_CR39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/bdr2.1857","volume":"113","author":"V Kancherla","year":"2021","unstructured":"Kancherla V, Koning J, Biluts H, Woldemariam M, Kibruyisfaw Z, Belete A, et al. Projected impact of mandatory food fortification with folic acid on neurosurgical capacity needed for treating spina bifida in Ethiopia. Birth Defects Res. 2021;113(5):393\u20138.","journal-title":"Birth Defects Res"},{"issue":"10","key":"9763_CR40","doi-asserted-by":"publisher","first-page":"e172222","DOI":"10.1001\/jamapediatrics.2017.2222","volume":"171","author":"R Zash","year":"2017","unstructured":"Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, et al. Comparative safety of antiretroviral treatment regimens in pregnancy. JAMA Pediatr. 2017;171(10):e172222\u2013e.","journal-title":"JAMA Pediatr"},{"key":"9763_CR41","unstructured":"Organization WH. Update on the transition to dolutegravir-based antiretroviral therapy: report of a WHO meeting, 29\u201330 March 2022. World Health Organization; 2022."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09763-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09763-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09763-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T08:05:14Z","timestamp":1725264314000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09763-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9763"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09763-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"27 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the ethical review boards of the Hawassa University College of Medicine and Health Sciences institutional review board (IRB), with reference number (IRB\/076\/2022, dated December 10\/2022). The members of the ethics committee include Dr. Embiale Mengiste, Dr. Muhammed Ayalew and Dr. Freshet Assefa. Informed consent was waived based on the use of anonymized data from routine healthcare records.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"901"}}